An Insider Look at Vaccines: Yesterday, Today, Tomorrow

Publications
Published on:
December 21, 2021

The COVID-19 pandemic has put vaccines in the spotlight. The pandemic has given the industry a considerable boost, and with lessons learned during the development and roll-out of the COVID-19 vaccine, the industry is now armed with new technologies and is establishing population immunity. 

To understand how the vaccine industry has changed over the last 20 years, where we are today, and what the future looks like, we spoke to Bernd Schollmeier, Vice President of Global Market Access Vaccines at Alira Health, and a vaccine expert with more than 30 years of experience in the field.

What is the difference between the pre-pandemic vaccine world and the vaccine world today?

For the last 40 years, there’s been an interesting dynamic in the vaccine world.  From the 1980s  through 2000, we saw 20 busy years. However, since then there have not been a lot of innovations in the vaccines field, except for HPV. There are several reasons for this lack of innovation. First, costs. The production process of vaccines is both complicated and expensive, and it may take up to two years to produce just a single dose of vaccine which has made vaccines an unattractive investment.  

Secondly, the industry’s regulatory landscape is very challenging. Vaccines are the best-controlled medicines in the world—in order to get a vaccine on the market, a producer needs to carry out considerably more extensive trials compared to other medicines. 

For these reasons, vaccines have not been seen as attractive ventures for pharmaceutical companies for a while. Some even gave up their activities or sold their vaccine portfolios. However, outbreaks like EBOLA, MERS, and SARS Cov1 showed that the new vaccines will be needed in the future. This brings us where we are today—in a renaissance of vaccines—and it’s in full swing. And in our pandemic world, the spotlight is once again on vaccines. 

What are the learnings from the pandemic?

The vaccine world has learned a lot from the COVID-19 pandemic, and we’ve also gotten some clear learnings for the world at large, including: 

  • There is a need for better education and awareness around vaccines for the global population—specifically that vaccines are effective and safe. 
  • Reaching a certain vaccination rate is critical—and a specific focus on closing the gap around non-vaccinated people is necessary to achieving this goal. 
  • Countries need to prioritize local production for medical equipment, like masks and disinfectants, so they’re prepared for pandemics of any kind that may disrupt the supply chain. 
  • Implementation of an early warning system that emphasizes collaboration and transparency across both industry and government players is crucial. 
  • We need to continue to explore existing techniques for novel applications like mRNA, work on more vaccines, and keep expanding on the existing progress in science. 
What are the biggest challenges the vaccine industry is currently facing?

Nature never stops—we will see mutations of existing germs; viruses and bacteria will continue to mutate. We will see new pathogens on the horizon—and we will also see great progress in universal flu vaccines and immunization against upcoming pathogens like Zika or Chikungunya Virus. Additionally, global warming and climate change are already changing the landscape of endemic diseases, and this should encourage companies to look closely at the vaccine industry.  

How are the dynamics in the vaccine world after this growth from the pandemic?

What we are learning now during the pandemic will become our best asset for similar situations in the future.  

I can also imagine new follow-up vaccines developed on the mRNA platforms, such as Influenza, RSV, and the combination of different vaccines. We are also seeing traction on other technologies, such as whole-cell vaccines currently in development and will be complementary to the existing technologies.  

Why did Alira Health decide to enter the world of vaccines?

We are seeing a lot of traction in the industry, as well as interest in vaccine production. To support companies in a challenging payer environment, we created a dedicated vaccine division in our Global Market Access department to provide a variety of solutions that maximize patient access and the gross-to-net value of the product across the full product lifecycle. 

About Bernd Schollmeier, Vice President of Global Market Access Vaccines 

Bernd brings over 30 years of vaccine experience in both consulting and the pharmaceutical industry to his role at Alira Health. His previous roles include sales, marketing, policy, patient engagement, corporate communications, and market access positions at several local, national, and global vaccine industry players. He’s been responsible for a range of global pricing and market access initiatives for vaccines—delivering a range of solutions across development and strategic market access considerations for trial design to value demonstration in P&R negotiations as well as commercialization strategies. Bernd holds an MSc in Economics. 

Bernd Schollmeier

Related news

M&A MedTech Pharma
News January 13, 2022
Alira Health Secures an Additional $40M in Funding, Led by Creadev
We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. We intend to use the funds to invest in solutions that actively engage patients(...)
Biometrics Clinical
Events January 11, 2022
Event: Maximise the Effectiveness of Your CRO Partnership: Practical Guide
Pharma
Events December 23, 2021
Event: Presentation of the 2021 BioRegion Report
We are thrilled to announce that Alira Health has contributed to the BioRegion Report 2021,
Clinical
Publications December 13, 2021
How—and Why—the Role of Clinical Data Manager is Changing
The relationship between Sponsor and CRO is a critical aspect of an effective and timely clinical trial; when the relationship is transparent and smooth, the benefit is seen by all parties.
Advanced Analytics Digital Health Pharma Research & Development
Publications December 10, 2021
Leveraging Data Intelligence for Effective Opportunity Screening and Prioritization in Drug Discovery
Our biotech client needed an innovative, effective way to identify which binding sites and therapeutic indications they should target for the development of new therapeutic agents for(...)
Pharma
Events November 21, 2021
Webinar: RWE in Pharma: An Expert Panel Discussion
Join Catia Proenca, PhD, for a webinar on RWE in Pharma.
Clinical Digital Health MedTech Pharma
News November 16, 2021
Alira Health Further Expands its Digital Healthcare Platform with the Acquisition of Patchai
We acquired Patchai, a digital health technology company headquartered in Italy. Patchai offers intelligent digital health solutions that engage and empower patients in clinical research(...)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.